GENE ONLINE|News &
Opinion
Blog

2022-01-21| Asia-PacificManufacturing

South Korea’s SK Inc., Develops Its CDMO Capabilities via Investment in the Center for Breakthrough Medicines

by Eduardo Longoria
Share To
To come along with the clinical trials conducted by one of SK Inc.’s child companies, SK biopharmaceuticals, SK is taking a wider view of the future and investing in CMO infrastructure with CBM. This is already in the wake of the 2021 creation of SK Pharmateco and acquiring of AMPAC Fine Chemicals, SK biotek, SK biotech Ireland, and Yposkesi. 

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
Revolutionary Technology Aims to Detect and Prevent Dementia and Mental Illness
2023-09-22
Connecting Global Biotech, Thailand’s Largest Biotech Event Takes Center Stage
2023-09-22
BIOHK2023: A place where biotechnology meets financial economics
2023-09-21
Connecting the Dots: TCELS Leads the Way for Thailand’s Life Sciences and Healthcare Innovations
2023-09-20
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
Dreams and Nightmares: the Mysterious Activities of the Brain During Deep Sleep
2023-09-20
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
READ MORE
EVENT
2023-10-04
BioFuture 2023
New York city,USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top